Duration of Tamoxifen Use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

PURPOSE: Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. METHODS: We studied 1504 women with a known BRCA1 or BRCA2 mutat...

詳細記述

保存先:
書誌詳細
主要な著者: Gronwald, Jacek, Robidoux, Andre, Kim-Sing, Charmaine, Tung, Nadine, Lynch, Henry T., Foulkes, William D., Manoukian, Siranoush, Ainsworth, Peter, Neuhausen, Susan, Demsky, Rochelle, Eisen, Andrea, Singer, Christian F., Saal, Howard, Senter, Leigha, Eng, Charis, Weitzel, Jeffrey, Moller, Pal, Gilchrist, Dawna M., Olopade, Olufunmilayo, Ginsburg, Ophira, Sun, Ping, Huzarski, Tomasz, Lubinski, Jan, Narod, Steven A.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4131437/
https://ncbi.nlm.nih.gov/pubmed/24951267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3026-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料